2nd Quarter - Report

COVIDIEN LP for COVIDIEN LP

Firm
Client
Income
—
Expenses
$760,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Economics/Economic Development ECN

H.R. 2052/S. 1023: Global Investments in American Jobs Act of 2013 (all provisions).

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —

Contacted: Executive Office of the President (EOP); State, Dept of (DOS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Energy, Dept of

Bills named: S. 1023 (113th), H.R. 2052 (113th)

Immigration IMM

Issues related to immigration reform.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
TIMOTHY MCBRIDE —

Contacted: Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); State, Dept of (DOS); Energy, Dept of; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Issues involving controlled substances and pain and addiction drugs generally.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
CRAIG BURTON New Staff, Sen. Bill First (98-04).
WILLIAM FRANCO —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: Office of Science & Technology Policy (OSTP); State, Dept of (DOS); Energy, Dept of; Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues relating to sequestration of the medical device user fees.; Issues related to reimbursements for Transcutaneous Electronic Stimulation (TENS) therapy for chronic low back pain; Issues regarding shortages of nuclear isotopes used in production of nuclear medicine.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
CRAIG BURTON New Staff, Sen. Bill First (98-04).
WILLIAM FRANCO —
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: Energy, Dept of; Office of Science & Technology Policy (OSTP); State, Dept of (DOS); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

S. 232: Medical Device Access and Innovation Protection Act (all provisions) ; H.R. 523: Protect Medical Innovation (all provisions); Issues related to the implementation of the Medical Device Tax; Issues related to the repeal of the Medical Device Tax; International tax on foreign direct investment; Corporate Tax Reform generally; S. 95: Student Loan Affordability Act of 2013 (provisions pertaining to international tax).

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); State, Dept of (DOS); Food & Drug Administration (FDA); SENATE; Energy, Dept of

Bills named: S. 95 (113th), H.R. 523 (113th), S. 232 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.